Conferences
ESMO 2024: Invited Discussant: Efficacy of SPLASH and UpFrontPSMA Trials
September 15, 2024
ESMO 2024: Novel Serum Glycoproteomic Biomarkers Predict Response to Nivolumab plus Cabozantinib Versus Sunitinib in Advanced RCC: Analysis from CheckMate 9ER
September 15, 2024
ESMO 2024: Phase 2 Study of Futibatinib plus Pembrolizumab in Patients with Advanced/Metastatic Urothelial Carcinoma: Final Analysis of Efficacy and Safety
September 15, 2024
ESMO 2024: UpFrontPSMA : A Randomized Phase II Study of Sequential 177Lu-PSMA-617 and Docetaxel versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
September 15, 2024
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor (SPLASH)
September 15, 2024
ESMO 2024: Radioligand Theranostics in Prostate Cancer: Status Quo and New Developments
September 15, 2024
ESMO 2024: Discussion of Late Breaking Abstracts 76, 77 and 1694MO
September 15, 2024
ESMO 2024: Updates in Penile Cancer
September 15, 2024
ESMO 2024: Non-Clear Cell RCC
September 15, 2024
ESMO 2024: CARE1 Pragmatic Clinical Trial - First Line Randomised Study Platform to Optimize Treatment in Patients with Metastatic Renal Cell Carcinoma
September 15, 2024
ESMO 2024: T Cell Engagers in Prostate Cancer
September 15, 2024
ESMO 2024: DLL-3 Targeted Therapy for Neuroendocrine Prostate Cancer
September 15, 2024